The Impact of Sitagliptin on Sodium Valproate-Induced Autism in a Mouse Model

Background:Autism spectrum disorder (ASD), a neurodevelopmental disease, is described by problems with social interaction and communication that arise at an early age. The only approved drugs for the treatment of ASD are risperidone and aripiprazole. Objectives:The aim of the article is to explore t...

Full description

Saved in:
Bibliographic Details
Main Authors: Ahmed Sudan Abbas, Selman Mohammed Selman, Alaa Jafear Mahrath
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2024-09-01
Series:Medical Journal of Babylon
Subjects:
Online Access:https://journals.lww.com/10.4103/MJBL.MJBL_398_23
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background:Autism spectrum disorder (ASD), a neurodevelopmental disease, is described by problems with social interaction and communication that arise at an early age. The only approved drugs for the treatment of ASD are risperidone and aripiprazole. Objectives:The aim of the article is to explore the potential therapeutic effects of sitagliptin on the induced offspring model of autism. Also, to evaluate the effect of sitagliptin on interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). Materials and Methods:We induced the disorder in mice by injecting pregnant mice with sodium valproate (600 mg/kg). Prenatal sodium valproate–exposed mice were split into four different groups, with two experimental groups taking sitagliptin (10 mg/kg and 15 mg/kg) and risperidone (1 mg/kg), and a control group receiving normal saline. Behavioral tests, including social interaction assessments were divided into three phases: habituation, familiarization, and testing, and lasted for 15 min, were conducted on postnatal day 65; also, anti-inflammatory marker assessments like TNF-α and IL-6 were conducted on postnatal day 66. Results:The study found that sitagliptin significantly improved behavioral disorders (social communication) and reduced neuro-inflammation in the brain. Sitagliptin therapy forcefully enhanced the cognitive function of ASD mice by regulating neurogenesis that could be connected with the powerful antioxidant and anti-inflammatory actions that sitagliptin possesses. Conclusion:Sitagliptin showed potent anxiolytic and anti-inflammatory properties that improved behavioral activities in the mice. These findings suggest that sitagliptin could be promising a potential treatment option for individuals with ASD.
ISSN:1812-156X
2312-6760